Breaking News Instant updates and real-time market news.

HBI

Hanesbrands

$18.28 /

+0.695 (+3.95%)

07:38
11/04/21
11/04
07:38
11/04/21
07:38

Hanesbrands sees Q4 EPS 40c-45c, consensus 42c

Sees Q4 revenue $$1.71B-$1.78B , consensus $1.75B.

  • 04

    Nov

OTHER BREAKING NEWS FROM THE FLY

Periodicals
Starboard-backed group made $64 per share bid to buy Kohl's, WSJ reports » 14:31
01/22/22
01/22
14:31
01/22/22
14:31
KSS

Kohl's

$46.83 /

-1.24 (-2.58%)

, ACTG

Acacia Research

$4.34 /

-0.03 (-0.69%)

A group led by Acacia…

A group led by Acacia Research (ACTG), which is controlled by activist investor Starboard Value, offered to buy Kohl's (KSS) for $64 per share in cash, a 37% premium to Friday's closing price of $46.84 and an offer that values the department store operator at roughly $9B, reported The Wall Street Journal's Cara Lombardo, citing people familiar with the matter. There are no guarantees that the group will ultimately line up all the funding needed and make a firm offer, but the bidders told the company they have assurances from bankers about being able to get financing for the bid, sources added. Previously, Reuters' Svea Herbst-Bayliss reported that Starboard-backed Acacia had reached out to Kohl's to express interest in making a bid. Reference Link

ShowHide Related Items >><<
KSS Kohl's
$46.83 /

-1.24 (-2.58%)

ACTG Acacia Research
$4.34 /

-0.03 (-0.69%)

KSS Kohl's
$46.83 /

-1.24 (-2.58%)

01/07/22 UBS
Kohl's downgraded to Sell from Neutral at UBS
01/04/22 JPMorgan
Kohl's price target lowered to $55 from $73 at JPMorgan
01/03/22 Guggenheim
Nike remains a 'Best Idea' at Guggenheim heading into 2022
11/19/21 Jefferies
Kohl's price target raised to $75 at Jefferies on higher margin likelihood
ACTG Acacia Research
$4.34 /

-0.03 (-0.69%)

KSS Kohl's
$46.83 /

-1.24 (-2.58%)

KSS Kohl's
$46.83 /

-1.24 (-2.58%)

ACTG Acacia Research
$4.34 /

-0.03 (-0.69%)

KSS Kohl's
$46.83 /

-1.24 (-2.58%)

ACTG Acacia Research
$4.34 /

-0.03 (-0.69%)

KSS Kohl's
$46.83 /

-1.24 (-2.58%)

Periodicals
Good time to buy Netflix stock, Barron's says » 10:01
01/22/22
01/22
10:01
01/22/22
10:01
NFLX

Netflix

$396.95 /

-111.26 (-21.89%)

, DIS

Disney

$137.39 /

-10.225 (-6.93%)

, AAPL

Apple

$162.41 /

-2.13 (-1.29%)

Netflix (NFLX) shares…

Netflix (NFLX) shares have been struggling for months. Heading into this past week's fateful fourth-quarter earnings report, there were worries about increased competition from Walt Disney (DIS), Apple (AAPL), and others, along with consumers' reaction to a recent price hike, Eric J. Savitz writes in this week's edition of Barron's. As it turned out, Thursday's report was a big deal, just not in the way that bulls would have liked. Netflix missed subscriber estimates, the only number that matters to investors, the author notes. Netflix shares plunged more than 20% following results, and what makes the whole situation more worrisome is that Netflix couldn't cleanly explain its soft outlook, Savitz adds. Despite this quarter's terrible reviews, it might be time to start nibbling, he argues. Reference Link

ShowHide Related Items >><<
NFLX Netflix
$396.95 /

-111.26 (-21.89%)

DIS Disney
$137.39 /

-10.225 (-6.93%)

AAPL Apple
$162.41 /

-2.13 (-1.29%)

NFLX Netflix
$396.95 /

-111.26 (-21.89%)

01/21/22 Cowen
Netflix price target lowered to $600 from $750 at Cowen
01/21/22 Monness Crespi
Netflix downgraded to Neutral from Buy at Monness Crespi
01/21/22 Raymond James
Netflix shares appropriately valued after Q4 report, says Raymond James
01/21/22 Canaccord
Netflix price target lowered to $600 from $750
DIS Disney
$137.39 /

-10.225 (-6.93%)

01/18/22 MoffettNathanson
Disney price target lowered to $165 from $175 at MoffettNathanson
01/14/22 Guggenheim
Disney downgraded to Neutral at Guggenheim on slower profit climb
01/14/22 Wedbush
Apple pursuing sports content would be 'right move at right time,' says Wedbush
01/14/22 JPMorgan
Disney remains top pick in media at JPMorgan
AAPL Apple
$162.41 /

-2.13 (-1.29%)

01/21/22 Wells Fargo
Apple price target raised to $205 from $165 at Wells Fargo
01/20/22 Morgan Stanley
Apple December quarter upside appears largely priced in, says Morgan Stanley
01/18/22 Evercore ISI
Evercore says China data point to deceleration for Apple's iPhone in December
01/18/22 JPMorgan
Apple China shipments tracked lower in December, says JPMorgan
NFLX Netflix
$396.95 /

-111.26 (-21.89%)

DIS Disney
$137.39 /

-10.225 (-6.93%)

AAPL Apple
$162.41 /

-2.13 (-1.29%)

NFLX Netflix
$396.95 /

-111.26 (-21.89%)

DIS Disney
$137.39 /

-10.225 (-6.93%)

AAPL Apple
$162.41 /

-2.13 (-1.29%)

NFLX Netflix
$396.95 /

-111.26 (-21.89%)

DIS Disney
$137.39 /

-10.225 (-6.93%)

AAPL Apple
$162.41 /

-2.13 (-1.29%)

NFLX Netflix
$396.95 /

-111.26 (-21.89%)

DIS Disney
$137.39 /

-10.225 (-6.93%)

AAPL Apple
$162.41 /

-2.13 (-1.29%)

AAPL Apple
$162.41 /

-2.13 (-1.29%)

Periodicals
Goldman Sachs still a buy even after disappointing quarter, Barron's says » 09:55
01/22/22
01/22
09:55
01/22/22
09:55
GS

Goldman Sachs

$343.70 /

-4.67 (-1.34%)

his past week, Goldman…

his past week, Goldman shares fell 10%, leaving them 19% below their November high, after fourth-quarter earnings of $10.81 a share fell short of expectations for the first time in seven quarters, Andrew Bary writes in this week's edition of Barron's. The selloff provides an opportunity to invest in Wall Street's most prestigious investment bank and trading house at an attractive price, the author contends. Reference Link

ShowHide Related Items >><<
GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

01/20/22 Citi
Goldman Sachs price target lowered to $455 from $480 at Citi
01/19/22 Barclays
Goldman Sachs price target lowered to $505 from $556 at Barclays
01/19/22 BMO Capital
Goldman Sachs price target lowered to $448 from $455 at BMO Capital
01/19/22 Oppenheimer
Goldman Sachs price target lowered to $574 from $598 at Oppenheimer
GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

Periodicals
Morgan Stanley, BofA, Wells won earnings season, all worth buying, Barron's says » 09:52
01/22/22
01/22
09:52
01/22/22
09:52
MS

Morgan Stanley

$98.92 /

-0.94 (-0.94%)

, BAC

Bank of America

$44.92 /

-0.83 (-1.81%)

, WFC

Wells Fargo

$53.66 /

-1.33 (-2.42%)

Of the six big banks that…

Of the six big banks that posted fourth-quarter results this month, only three saw their stocks rise on their respective earnings day: Morgan Stanley (MS), Bank of America (BAC), and Wells Fargo (WFC), Carleton English writes in this week's edition of Barron's. The banks differ in areas of focus, but they share one key thing: better expense management than their less fortunate peers, he adds. Looking ahead, an investor can't go wrong choosing any of these three stocks, albeit for very different reasons, the author contends. Reference Link

ShowHide Related Items >><<
WFC Wells Fargo
$53.66 /

-1.33 (-2.42%)

MS Morgan Stanley
$98.92 /

-0.94 (-0.94%)

BAC Bank of America
$44.92 /

-0.83 (-1.81%)

MS Morgan Stanley
$98.92 /

-0.94 (-0.94%)

01/03/22 Barclays
Morgan Stanley price target raised to $123 from $110 at Barclays
12/03/21
Fly Intel: Top five analyst upgrades
12/03/21 Citi
Morgan Stanley upgraded to Buy from Neutral at Citi
10/18/21 Citi
Morgan Stanley price target raised to $105 from $100 at Citi
BAC Bank of America
$44.92 /

-0.83 (-1.81%)

01/20/22 Argus
Bank of America price target raised to $55 from $50 at Argus
01/12/22 Citi
Citi opens '30-Day Positive Catalyst Watch' on Bank of America
01/11/22 Piper Sandler
Bank of America the large cap bank stock to own for 2022, says Piper Sandler
01/06/22 JPMorgan
Bank of America price target raised to $52.50 from $50 at JPMorgan
WFC Wells Fargo
$53.66 /

-1.33 (-2.42%)

01/18/22 Argus
Wells Fargo price target raised to $65 from $55 at Argus
01/18/22 Raymond James
Wells Fargo price target raised to $65 from $58 at Raymond James
01/17/22 Keefe Bruyette
Wells Fargo price target raised to $67 from $57 at Keefe Bruyette
01/12/22 Piper Sandler
Wells Fargo upgraded to Overweight with $64 target at Piper Sandler
WFC Wells Fargo
$53.66 /

-1.33 (-2.42%)

MS Morgan Stanley
$98.92 /

-0.94 (-0.94%)

BAC Bank of America
$44.92 /

-0.83 (-1.81%)

WFC Wells Fargo
$53.66 /

-1.33 (-2.42%)

MS Morgan Stanley
$98.92 /

-0.94 (-0.94%)

BAC Bank of America
$44.92 /

-0.83 (-1.81%)

WFC Wells Fargo
$53.66 /

-1.33 (-2.42%)

MS Morgan Stanley
$98.92 /

-0.94 (-0.94%)

WFC Wells Fargo
$53.66 /

-1.33 (-2.42%)

MS Morgan Stanley
$98.92 /

-0.94 (-0.94%)

BAC Bank of America
$44.92 /

-0.83 (-1.81%)

Periodicals
Mr. Cooper Group stock looking like a buy, Barron's says » 09:47
01/22/22
01/22
09:47
01/22/22
09:47
COOP

Mr. Cooper

$42.15 /

-0.85 (-1.98%)

If rates keep rising as…

If rates keep rising as the Federal Reserve tightens monetary policy, housing stocks will struggle as home loans grow less affordable. The outlook doesn't look great for mortgage originators either, with volumes likely to fall, Daren Fonda writes in this week's edition of Barron's. But one mortgage company could be a winner: Mr. Cooper Group, the author contends. The company, rebranded from Nationstar Mortgage in 2017, originates loans like other housing lenders. But about half its revenue comes from servicing-processing payments, handling escrows, and dealing with loan issues, he adds. Cooper earns a higher percentage of its revenue from servicing than any other major mortgage company. And the business gains value in a rising-rate climate-boosting the asset on Cooper's balance sheet, Fonda argues. Reference Link

ShowHide Related Items >><<
COOP Mr. Cooper
$42.15 /

-0.85 (-1.98%)

COOP Mr. Cooper
$42.15 /

-0.85 (-1.98%)

01/10/22 Barclays
Mr. Cooper price target raised to $46 from $39 at Barclays
11/02/21 Piper Sandler
Mr. Cooper price target raised to $60 from $48 at Piper Sandler
09/21/21 Piper Sandler
Mr. Cooper offers attractive risk/reward profile, says Piper Sandler
04/21/21 Barclays
Mr. Cooper downgraded to Equal Weight from Overweight at Barclays
COOP Mr. Cooper
$42.15 /

-0.85 (-1.98%)

COOP Mr. Cooper
$42.15 /

-0.85 (-1.98%)

Periodicals
Many ways to play Microsoft, Activision Blizzard deal, Barron's says » 09:44
01/22/22
01/22
09:44
01/22/22
09:44
MSFT

Microsoft

$295.81 /

-5.71 (-1.89%)

, ATVI

Activision Blizzard

$81.36 /

-0.43 (-0.53%)

, TTWO

Take-Two

$164.84 /

+0.3 (+0.18%)

, ZNGA

Zynga

$9.01 /

-0.035 (-0.39%)

, EA

Electronic Arts

$139.10 /

+0.15 (+0.11%)

Microsoft (MSFT)…

Microsoft (MSFT) announced on Tuesday that it had agreed to buy Activision Blizzard (ATVI) in an all-cash deal valued at nearly $69 billion, and speculation sparked a rally in shares of Electronic Arts (EA) Take-Two Interactive (TTWO), Eric J. Savitz writes in this week's edition of Barron's. For investors, there are multiple ways to play the merger. Anyone convinced the deal will go through can buy Activision shares. But there's plenty of risk, and the potential reward is capped by the deal price, limiting upside to about 15%, the author notes. Investors can also bet on the potential of additional consolidation by buying shares of takeover candidates like EA, Take-Two, and the other game publishers that rallied this past week, Savitz contends. Shares of mobile videogame maker Zynga (ZNGA) soared earlier this month after Take-Two said it was buying the company for $12.7 billion. But the better, less speculative bet is Microsoft itself, he argued, adding that the stock has been a laggard over the past few months, but seems well-positioned for double-digit earnings growth as far as the eye can see. Reference Link

ShowHide Related Items >><<
ZNGA Zynga
$9.01 /

-0.035 (-0.39%)

TTWO Take-Two
$164.84 /

+0.3 (+0.18%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

EA Electronic Arts
$139.10 /

+0.15 (+0.11%)

ATVI Activision Blizzard
$81.36 /

-0.43 (-0.53%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

01/20/22 Morgan Stanley
Sony named a 'Research Tactical Idea' at Morgan Stanley
01/20/22 BMO Capital
Activision Blizzard price target raised to $95 from $90 at BMO Capital
01/20/22 Citi
Microsoft price target lowered to $376 from $407 at Citi
01/19/22 BTIG
Zynga downgraded to Neutral from Buy at BTIG
ATVI Activision Blizzard
$81.36 /

-0.43 (-0.53%)

01/19/22 RBC Capital
RBC Capital positive on Microsoft acquisition of Activision Blizzard
TTWO Take-Two
$164.84 /

+0.3 (+0.18%)

01/19/22 Exane BNP Paribas
Take-Two upgraded to Outperform from Neutral at Exane BNP Paribas
01/19/22 Deutsche Bank
Activision Blizzard downgraded to Hold from Buy at Deutsche Bank
01/18/22 Truist
Activision Blizzard downgraded to Hold from Buy at Truist
ZNGA Zynga
$9.01 /

-0.035 (-0.39%)

01/19/22 Morgan Stanley
Zynga downgraded to Equal Weight from Overweight at Morgan Stanley
01/18/22 Stifel
Activision Blizzard deal shines positive light on video game group, says Stifel
01/18/22 Jefferies
Zynga downgraded to Hold from Buy at Jefferies
EA Electronic Arts
$139.10 /

+0.15 (+0.11%)

01/19/22 Atlantic Equities
Electronic Arts upgraded to Overweight from Neutral at Atlantic Equities
ZNGA Zynga
$9.01 /

-0.035 (-0.39%)

TTWO Take-Two
$164.84 /

+0.3 (+0.18%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

EA Electronic Arts
$139.10 /

+0.15 (+0.11%)

ATVI Activision Blizzard
$81.36 /

-0.43 (-0.53%)

ZNGA Zynga
$9.01 /

-0.035 (-0.39%)

TTWO Take-Two
$164.84 /

+0.3 (+0.18%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

EA Electronic Arts
$139.10 /

+0.15 (+0.11%)

ATVI Activision Blizzard
$81.36 /

-0.43 (-0.53%)

ZNGA Zynga
$9.01 /

-0.035 (-0.39%)

TTWO Take-Two
$164.84 /

+0.3 (+0.18%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

EA Electronic Arts
$139.10 /

+0.15 (+0.11%)

ZNGA Zynga
$9.01 /

-0.035 (-0.39%)

TTWO Take-Two
$164.84 /

+0.3 (+0.18%)

MSFT Microsoft
$295.81 /

-5.71 (-1.89%)

EA Electronic Arts
$139.10 /

+0.15 (+0.11%)

ATVI Activision Blizzard
$81.36 /

-0.43 (-0.53%)

On The Fly
Opening Day: Rhodium Enterprises postpones public debut in quiet IPO week » 09:31
01/22/22
01/22
09:31
01/22/22
09:31
SMSA

Samsara Vision

/

+

, NSTS

NSTS Bancorp

$12.54 /

+0.04 (+0.32%)

, TKLF

Yoshitsu

$29.20 /

-0.445 (-1.50%)

, PEV

Phoenix Motor

/

+

, NUVO

Nuvo Group

/

+

, CHO

Chobani

/

+

, CAST

FreeCast

/

+

, SMBA

Samba TV

/

+

, F

Ford

$20.65 /

-0.99 (-4.57%)

, DLTXF

DLT ASA

$1.60 /

+ (+0.00%)

, RHDM

Rhodium Enterprises

/

+

, GS

Goldman Sachs

$343.70 /

-4.67 (-1.34%)

, SPI

SPI Energy

$2.69 /

-0.255 (-8.66%)

In a quiet week for IPOs,…

ShowHide Related Items >><<
TKLF Yoshitsu
$29.20 /

-0.445 (-1.50%)

SPI SPI Energy
$2.69 /

-0.255 (-8.66%)

NSTS NSTS Bancorp
$12.54 /

+0.04 (+0.32%)

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

F Ford
$20.65 /

-0.99 (-4.57%)

SMSA Samsara Vision
/

+

NSTS NSTS Bancorp
$12.54 /

+0.04 (+0.32%)

TKLF Yoshitsu
$29.20 /

-0.445 (-1.50%)

PEV Phoenix Motor
/

+

NUVO Nuvo Group
/

+

CHO Chobani
/

+

CAST FreeCast
/

+

SMBA Samba TV
/

+

F Ford
$20.65 /

-0.99 (-4.57%)

01/20/22 Jefferies
Ford downgraded to Hold from Buy at Jefferies
01/14/22 RBC Capital
Ford downgraded to Sector Perform at RBC Capital on reduced near-term upside
01/14/22 RBC Capital
Ford downgraded to Sector Perform from Outperform at RBC Capital
01/13/22 Deutsche Bank
Deutsche Bank sees 2022 guidance misses from these auto companies
DLTXF DLT ASA
$1.60 /

+ (+0.00%)

RHDM Rhodium Enterprises
/

+

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

01/20/22 Citi
Goldman Sachs price target lowered to $455 from $480 at Citi
01/19/22 Barclays
Goldman Sachs price target lowered to $505 from $556 at Barclays
01/19/22 BMO Capital
Goldman Sachs price target lowered to $448 from $455 at BMO Capital
01/19/22 Oppenheimer
Goldman Sachs price target lowered to $574 from $598 at Oppenheimer
SPI SPI Energy
$2.69 /

-0.255 (-8.66%)

09/27/21 Maxim
Maxim starts SPI Energy at Buy on contribution from EV initiatives
09/27/21 Maxim
SPI Energy initiated with a Buy at Maxim
GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

F Ford
$20.65 /

-0.99 (-4.57%)

  • 20
    Jan
  • 21
    Jan
GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

F Ford
$20.65 /

-0.99 (-4.57%)

SMSA Samsara Vision
/

+

PEV Phoenix Motor
/

+

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

F Ford
$20.65 /

-0.99 (-4.57%)

SPI SPI Energy
$2.69 /

-0.255 (-8.66%)

GS Goldman Sachs
$343.70 /

-4.67 (-1.34%)

F Ford
$20.65 /

-0.99 (-4.57%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold a symposium » 04:55
01/22/22
01/22
04:55
01/22/22
04:55
AGEN

Agenus

$2.70 /

-0.055 (-2.00%)

, AZN

AstraZeneca

$59.10 /

-1.1 (-1.83%)

, BAYRY

Bayer

$14.62 /

-0.26 (-1.75%)

, BMY

Bristol-Myers

$63.56 /

-1.045 (-1.62%)

, CRDF

Cardiff Oncology

$3.70 /

-0.18 (-4.65%)

, DSNKY

Daiichi Sankyo

$22.66 /

-0.03 (-0.13%)

, DCPH

Deciphera

$8.05 /

-0.1 (-1.23%)

, DNA

Ginkgo Bioworks

$5.27 /

+0.165 (+3.23%)

, ESALY

Eisai

$51.92 /

-0.78 (-1.48%)

, EXAS

Exact Sciences

$74.06 /

-2.005 (-2.64%)

, EXEL

Exelixis

$17.34 /

+0.29 (+1.70%)

, GH

Guardant Health

$70.17 /

-2.36 (-3.25%)

, HCM

Hutchmed

$28.82 /

-1.16 (-3.87%)

, IMMVF

Immunovia

$7.40 /

+ (+0.00%)

, INCY

Incyte

$74.77 /

-0.05 (-0.07%)

, IPSEY

Ipsen

$23.66 /

+0.38 (+1.63%)

, LLY

Eli Lilly

$243.12 /

-0.01 (-0.00%)

, MRK

Merck

$79.98 /

-0.765 (-0.95%)

, MRTX

Mirati Therapeutics

$114.10 /

-4.4 (-3.71%)

, NTRA

Natera

$62.74 /

-0.355 (-0.56%)

, NVCR

Novocure

$67.14 /

-2.9 (-4.14%)

, NVS

Novartis

$87.01 /

-1.18 (-1.34%)

, ORIC

Oric Pharmaceuticals

$10.96 /

-0.37 (-3.27%)

, PBLA

Panbela Therapeutics

$1.60 /

-0.09 (-5.33%)

, PFE

Pfizer

$52.78 /

-1.3 (-2.40%)

, SGEN

Seagen

$127.66 /

-4.85 (-3.66%)

, TPTX

Turning Point Therapeutics

$35.95 /

+0.07 (+0.20%)

, VCYT

Veracyte

$27.00 /

-0.69 (-2.49%)

, ZYME

Zymeworks

$11.20 /

-0.38 (-3.28%)

ASCO Gastrointestinal…

ASCO Gastrointestinal Cancers Symposium to be held in San Francisco on January 20-22. Webcast Link

ShowHide Related Items >><<
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

NVCR Novocure
$67.14 /

-2.9 (-4.14%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

HCM Hutchmed
$28.82 /

-1.16 (-3.87%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

ESALY Eisai
$51.92 /

-0.78 (-1.48%)

DSNKY Daiichi Sankyo
$22.66 /

-0.03 (-0.13%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

12/16/21 H.C. Wainwright
Agenus initiated with a Buy at H.C. Wainwright
12/06/21 B. Riley
B. Riley bullish on Novavax, Agenus amid Omicron spread
11/09/21 Evercore ISI
Evercore starts Agenus spinout MiNK Therapeutics with an Outperform
10/25/21 B. Riley
Agenus price target lowered to $11 from $12 at B. Riley
AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

12/30/21 SVB Leerink
SVB Leerink confident Adbry poses minimal competitive risk to Dupixent
12/16/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
12/16/21 Stifel
Adagio story 'even more complicated' after preprints on ADG20, says Stifel
12/12/21 Piper Sandler
Schrodinger MALT1 preclinical data supports IND filing in 1H22, says Piper
BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

11/15/21 AlphaValue/Baader
Bayer upgraded to Buy from Add at AlphaValue/Baader
11/10/21 JPMorgan
Bayer price target raised to EUR 75 from EUR 67 at JPMorgan
11/10/21 Morgan Stanley
Bayer price target raised to EUR 74 from EUR 71 at Morgan Stanley
11/10/21 Credit Suisse
Bayer price target raised to EUR 57 from EUR 55 at Credit Suisse
BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

01/10/22 Piper Sandler
Piper says Century Therapeutics' alliance with Bristol 'transformational'
01/03/22 Piper Sandler
Legend Biotech named a top pick for 2022 at Piper Sandler
12/21/21 Oppenheimer
Oppenheimer starts Cytokinetics at Outperform, sees 'blockbuster' potential
12/21/21 Piper Sandler
Legend Biotech initiated with an Overweight at Piper Sandler
CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

12/07/21 Baird
Cardiff Oncology initiated with an Outperform at Baird
11/18/21 Piper Sandler
Cardiff investment by Pfizer 'some nice validation,' says Piper Sandler
09/09/21 Maxim
Cardiff Oncology price target raised to $25 from $20 at Maxim
09/09/21 Piper Sandler
Cardiff colorectal cancer data 'very consistent,' says Piper Sandler
DSNKY Daiichi Sankyo
$22.66 /

-0.03 (-0.13%)

10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
03/15/21 Citi
Citi opens 'positive catalyst watch' on Daiichi Sankyo
03/08/21 Goldman Sachs
Daiichi Sankyo upgraded to Buy from Neutral at Goldman Sachs
DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

12/01/21 H.C. Wainwright
Deciphera price target lowered to $15 from $25 at H.C. Wainwright
11/30/21 Piper Sandler
Deciphera price target lowered to $11 from $14 at Piper Sandler
11/08/21 Barclays
Deciphera downgraded to Equal Weight at Barclays after GIST trial miss
11/08/21 Canaccord
Deciphera downgraded to Hold at Canaccord
DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

01/06/22 BTIG
BTIG starts Ginkgo Bioworks at Buy with $12 price target
01/06/22 BTIG
Ginkgo Bioworks initiated with a Buy at BTIG
11/29/21 Jefferies
Ginkgo Bioworks initiated with a Buy at Jefferies
10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
ESALY Eisai
$51.92 /

-0.78 (-1.48%)

01/13/22 Citi
Eisai downgraded to Neutral from Buy at Citi
10/08/21 Jefferies
Biogen price target lowered to $400 from $500 at Jefferies
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
06/25/21 Morgan Stanley
Eisai downgraded to Equal Weight from Overweight at Morgan Stanley
EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

11/03/21 BTIG
Exact Sciences price target lowered to $120 from $145 at BTIG
11/03/21 Craig-Hallum
Exact Sciences price target lowered to $133 from $144 at Craig-Hallum
11/03/21 Raymond James
Exact Sciences downgraded to Outperform from Strong Buy at Raymond James
11/03/21 Wells Fargo
Exact Sciences price target lowered to $95 from $120 at Wells Fargo
EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

11/18/21 Piper Sandler
Exelixis transferred with Overweight at Piper Sandler
11/03/21 H.C. Wainwright
Exelixis price target lowered to $52 from $65 at H.C. Wainwright
10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
GH Guardant Health
$70.17 /

-2.36 (-3.25%)

10/14/21 Cowen
Guardant Health coverage transferred at Cowen
08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
HCM Hutchmed
$28.82 /

-1.16 (-3.87%)

09/22/21
Fly Intel: Top five analyst downgrades
09/22/21 Goldman Sachs
Hutchmed downgraded to Neutral from Buy at Goldman Sachs
08/03/21 Jefferies
Hutchmed initiated with a Buy at Jefferies
07/13/21 Cantor Fitzgerald
Hutchmed price target raised to $45 from $40 at Cantor Fitzgerald
IMMVF Immunovia
$7.40 /

+ (+0.00%)

12/22/21 Kempen
Immunovia downgraded to Neutral from Buy at Kempen
INCY Incyte
$74.77 /

-0.05 (-0.07%)

01/18/22 RBC Capital
Incyte upgraded to Outperform at RBC Capital on improving 2022 setup
01/18/22 RBC Capital
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/03/22 Guggenheim
Incyte price target lowered to $104 from $118 at Guggenheim
12/31/21 Benchmark
Incyte, Nektar, Compass Therapeutics named best biotech picks at Benchmark
IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

01/11/22 Bryan Garnier
Ipsen upgraded to Buy from Neutral at Bryan Garnier
01/06/22 Societe Generale
Ipsen upgraded to Buy from Hold at Societe Generale
01/04/22 JPMorgan
Ipsen downgraded to Neutral from Overweight at JPMorgan
11/24/21 Berenberg
Ipsen initiated with a Hold at Berenberg
LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

01/21/22 DZ Bank
Eli Lilly upgraded to Buy from Hold at DZ Bank
01/14/22 BofA
Biogen price target lowered to $245 from $275 at BofA
01/12/22 Wells Fargo
CMS proposed coverage with evidence 'a clear negative,' says Wells Fargo
01/05/22 Mizuho
Eli Lilly price target raised to $302 from $272 at Mizuho
MRK Merck
$79.98 /

-0.765 (-0.95%)

12/23/21 Mizuho
Mizuho sees market for both Merck's molnupiravir, Pfizer's Paxlovid
12/17/21 Goldman Sachs
Goldman starts Merck at Conviction Buy with market undervaluing assets
12/17/21 Goldman Sachs
Merck initiated with a Conviction Buy at Goldman Sachs
12/16/21 Daiwa
Merck initiated with a Neutral at Daiwa
MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/18/21 BMO Capital
Mirati Therapeutics initiated with an Outperform at BMO Capital
09/22/21 Stifel
Mirati Therapeutics initiated with a Buy at Stifel
09/22/21 Citi
Mirati Therapeutics price target raised to $244 from $232 at Citi
NTRA Natera
$62.74 /

-0.355 (-0.56%)

01/12/22 BTIG
Natera price target lowered to $150, named one of top 2022 picks at BTIG
01/05/22 Piper Sandler
Natera assumed with an Overweight at Piper Sandler
01/04/22 Canaccord
Natera weakness a buying opportunity, says Canaccord
11/05/21 Baird
Natera price target raised to $152 from $145 at Baird
NVCR Novocure
$67.14 /

-2.9 (-4.14%)

01/20/22 Truist
Novocure upgraded to Buy on more favorable risk-reward at Truist
01/20/22 Truist
Novocure upgraded to Buy from Hold at Truist
01/11/22 Wells Fargo
Novocure price target lowered to $70 from $105 at Wells Fargo
01/10/22 Piper Sandler
Novocure price target lowered to $125 from $130 at Piper Sandler
NVS Novartis
$87.01 /

-1.18 (-1.34%)

01/12/22 Alliance Global Partners
OpGen price target lowered to $3 from $4.35 at Alliance Global Partners
01/10/22 Citi
Novartis resumed with a Buy at Citi
01/06/22 Piper Sandler
Piper want to own Alnylam shares ahead of expected vutrisiran approval
12/15/21 Berenberg
Novartis price target lowered to CHF 85 from CHF 88 at Berenberg
ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

10/08/21 Baird
Oric Pharmaceuticals price target lowered to $26 from $47 at Baird
10/08/21 Citi
Oric Pharmaceuticals price target lowered to $22 from $33 at Citi
10/08/21 H.C. Wainwright
Oric Pharmaceuticals price target lowered to $30 from $53 at H.C. Wainwright
10/07/21 Oppenheimer
Oppenheimer remains bullish on Oric Pharmaceuticals, says selloff 'overdone'
PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
03/10/21 Maxim
Panbela Therapeutics initiated with a Buy at Maxim
PFE Pfizer
$52.78 /

-1.3 (-2.40%)

01/14/22 BMO Capital
Pfizer price target raised to $76 from $60 at BMO Capital
01/11/22 BofA
Pfizer added to US 1 List; Goldman Sachs removed at BofA
01/10/22 Wedbush
Beam Therapeutics price target raised to $159 from $148 at Wedbush
01/05/22 BofA
Pfizer upgraded to Buy from Neutral at BofA
SGEN Seagen
$127.66 /

-4.85 (-3.66%)

11/08/21 Wolfe Research
Seagen initiated with a Peer Perform at Wolfe Research
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
10/28/21 Piper Sandler
Seagen price target raised to $165 from $160 at Piper Sandler
TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

01/21/22 Oppenheimer
Turning Point Therapeutics price target lowered to $105 from $115 at Oppenheimer
01/03/22 Guggenheim
Turning Point Therapeutics price target lowered to $107 from $118 at Guggenheim
12/22/21 Roth Capital
Turning Point FDA feedback appears positive, says Roth Capital
12/06/21 Cowen
Turning Point Therapeutics initiated with an Outperform at Cowen
VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

01/06/22 Stephens
Veracyte initiated with Overweight, named best idea at Stephens
11/18/21 Goldman Sachs
Veracyte reinstated with a Buy at Goldman Sachs
11/10/21 Raymond James
Veracyte price target raised to $62 from $50 at Raymond James
06/28/21 Raymond James
Veracyte price target raised to $50 from $45 at Raymond James
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

12/10/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
12/10/21 SVB Leerink
Zymeworks upgraded to Outperform from Market Perform at SVB Leerink
12/09/21 Raymond James
Zymeworks downgraded to Outperform from Strong Buy at Raymond James
11/17/21 Guggenheim
Zymeworks assumed with a Neutral at Guggenheim
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

TPTX Turning Point Therapeutics
$35.95 /

+0.07 (+0.20%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

PBLA Panbela Therapeutics
$1.60 /

-0.09 (-5.33%)

ORIC Oric Pharmaceuticals
$10.96 /

-0.37 (-3.27%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

NVCR Novocure
$67.14 /

-2.9 (-4.14%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

  • 11
    Nov
  • 22
    Jul
  • 05
    Feb
ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

NTRA Natera
$62.74 /

-0.355 (-0.56%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

ESALY Eisai
$51.92 /

-0.78 (-1.48%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

ZYME Zymeworks
$11.20 /

-0.38 (-3.28%)

VCYT Veracyte
$27.00 /

-0.69 (-2.49%)

SGEN Seagen
$127.66 /

-4.85 (-3.66%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

MRTX Mirati Therapeutics
$114.10 /

-4.4 (-3.71%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

IPSEY Ipsen
$23.66 /

+0.38 (+1.63%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

GH Guardant Health
$70.17 /

-2.36 (-3.25%)

EXEL Exelixis
$17.34 /

+0.29 (+1.70%)

EXAS Exact Sciences
$74.06 /

-2.005 (-2.64%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

DCPH Deciphera
$8.05 /

-0.1 (-1.23%)

CRDF Cardiff Oncology
$3.70 /

-0.18 (-4.65%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

BAYRY Bayer
$14.62 /

-0.26 (-1.75%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

PFE Pfizer
$52.78 /

-1.3 (-2.40%)

NVS Novartis
$87.01 /

-1.18 (-1.34%)

MRK Merck
$79.98 /

-0.765 (-0.95%)

LLY Eli Lilly
$243.12 /

-0.01 (-0.00%)

INCY Incyte
$74.77 /

-0.05 (-0.07%)

DNA Ginkgo Bioworks
$5.27 /

+0.165 (+3.23%)

BMY Bristol-Myers
$63.56 /

-1.045 (-1.62%)

AZN AstraZeneca
$59.10 /

-1.1 (-1.83%)

AGEN Agenus
$2.70 /

-0.055 (-2.00%)

Periodicals
Judge denies McDonald's motion to dismiss Byron Allen's suit, Bloomberg says  18:33
01/21/22
01/21
18:33
01/21/22
18:33
MCD

McDonald's

$254.64 /

+1.52 (+0.60%)

 
ShowHide Related Items >><<
MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

01/21/22 BTIG
Beyond Meat's expanded McPlant offering approaching 'national launch', says BTIG
01/19/22 Goldman Sachs
McDonald's price target raised to $287 from $284 at Goldman Sachs
01/14/22 Evercore ISI
Evercore ups Texas Roadhouse to Outperform on underappreciated recovery leverage
01/06/22 UBS
Texas Roadhouse upgraded to Buy from Neutral at UBS
MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

MCD McDonald's
$254.64 /

+1.52 (+0.60%)

Hot Stocks
Gilead says FDA grants expediated approval of Veklury sNDA » 18:25
01/21/22
01/21
18:25
01/21/22
18:25
GILD

Gilead

$68.50 /

+0.68 (+1.00%)

Gilead Sciences, Inc.…

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has granted expedited approval of a supplemental new drug application for Veklury for the treatment of non-hospitalized adult and adolescent patients who are at high risk of progression to severe COVID-19, including hospitalization or death. This approval expands the role of Veklury, which is the antiviral standard of care for the treatment of patients hospitalized with COVID-19. The expanded indication allows for Veklury to be administered in qualified outpatient settings that can administer daily intravenous infusions over three consecutive days. The FDA has also expanded the pediatric Emergency Use Authorization of Veklury to include non-hospitalized pediatric patients younger than 12 years of age who are at high risk of disease progression. These actions by the FDA come amidst a surge in COVID-19 cases and the reduced susceptibility to several anti-SARS-CoV-2 monoclonal antibodies due to the Omicron variant. In contrast, Veklury targets the highly conserved viral RNA polymerase, thereby retaining activity against existing SARS-CoV-2 variants of concern. In vitro laboratory testing shows that Veklury retains activity against the Omicron variant. To date, no major genetic changes have been identified in any of the known variants of concern that would significantly alter the viral RNA polymerase targeted by Veklury.

ShowHide Related Items >><<
GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

01/06/22 Morgan Stanley
Gilead downgraded to Equal Weight from Overweight at Morgan Stanley
12/22/21 Piper Sandler
Piper says Gilead vial compatibility issue for lenacapavir 'minor and fixable'
12/22/21 Morgan Stanley
Gilead's injectable lenacapavir hold likely temporary, says Morgan Stanley
12/15/21 Jefferies
Bloomin', Callaway, Newell among five 'Franchise Picks' additions at Jefferies
GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

GILD Gilead
$68.50 /

+0.68 (+1.00%)

Recommendations
Zalando price target lowered to EUR 104 from EUR 110 at Barclays » 17:40
01/21/22
01/21
17:40
01/21/22
17:40
ZLNDY

Zalando

$37.55 /

-0.81 (-2.11%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Zalando to EUR 104 from EUR 110 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
ZLNDY Zalando
$37.55 /

-0.81 (-2.11%)

ZLNDY Zalando
$37.55 /

-0.81 (-2.11%)

12/10/21 UBS
Zalando price target lowered to EUR 101 from EUR 110 at UBS
11/05/21 Morgan Stanley
Zalando price target lowered to EUR 92 from EUR 95 at Morgan Stanley
11/04/21 Barclays
Zalando price target lowered to EUR 110 from EUR 113 at Barclays
11/04/21 Credit Suisse
Zalando price target lowered to EUR 98 from EUR 106 at Credit Suisse
ZLNDY Zalando
$37.55 /

-0.81 (-2.11%)

Recommendations
UniCredit price target raised to EUR 15 from EUR 13.80 at Barclays » 17:39
01/21/22
01/21
17:39
01/21/22
17:39
UNCRY

UniCredit

$7.38 /

-0.2 (-2.64%)

Barclays analyst Paola…

Barclays analyst Paola Sabbione raised the firm's price target on UniCredit to EUR 15 from EUR 13.80 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

12/13/21 UBS
UniCredit price target raised to EUR 19.50 from EUR 14.70 at UBS
12/13/21 Credit Suisse
UniCredit price target raised to EUR 15.10 from EUR 13.80 at Credit Suisse
12/13/21 Citi
UniCredit price target raised to EUR 15.70 from EUR 14.10 at Citi
12/10/21 Barclays
UniCredit price target raised to EUR 13.80 from EUR 11.60 at Barclays
UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

UNCRY UniCredit
$7.38 /

-0.2 (-2.64%)

Recommendations
Trainline price target lowered to 245 GBp from 280 GBp at Barclays » 17:38
01/21/22
01/21
17:38
01/21/22
17:38
TNLIF

Trainline

$4.32 /

+ (+0.00%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Trainline to 245 GBp from 280 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
TNLIF Trainline
$4.32 /

+ (+0.00%)

12/09/21 JPMorgan
Trainline price target lowered to 325 GBp from 358 GBp at JPMorgan
11/04/21 Barclays
Trainline price target lowered to 280 GBp from 340 GBp at Barclays
11/04/21 JPMorgan
Trainline price target lowered to 358 GBp from 399 GBp at JPMorgan
11/04/21 Morgan Stanley
Trainline price target lowered to 380 GBp from 400 GBp at Morgan Stanley
Recommendations
South32 price target lowered to 175 GBp from 180 GBp at Barclays » 17:38
01/21/22
01/21
17:38
01/21/22
17:38
SOUHY

South32

$14.69 /

-0.55 (-3.61%)

Barclays analyst Amos…

Barclays analyst Amos Fletcher lowered the firm's price target on South32 to 175 GBp from 180 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
SOUHY South32
$14.69 /

-0.55 (-3.61%)

01/14/22 Barclays
South32 price target lowered to 180 GBp from 200 GBp at Barclays
12/14/21 Investec
South32 initiated with a Buy at Investec
11/26/21 BMO Capital
South32 price target raised to 210 GBp from 200 GBp at BMO Capital
10/08/21 Barclays
South32 price target raised to 200 GBp from 150 GBp at Barclays
Recommendations
Scout24 price target raised to EUR 70 from EUR 65.50 at Barclays » 17:37
01/21/22
01/21
17:37
01/21/22
17:37
SCOTF

Scout24

$69.93 /

+ (+0.00%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross raised the firm's price target on Scout24 to EUR 70 from EUR 65.50 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
SCOTF Scout24
$69.93 /

+ (+0.00%)

01/20/22 Goldman Sachs
Scout24 resumed with a Neutral at Goldman Sachs
01/14/22 JPMorgan
Scout24 price target lowered to EUR 70 from EUR 71 at JPMorgan
12/13/21 Berenberg
Scout24 initiated with a Buy at Berenberg
12/09/21 JPMorgan
Scout24 upgraded to Overweight from Neutral at JPMorgan
Recommendations
Schibsted price target lowered to NOK 485 from NOK 565 at Barclays » 17:35
01/21/22
01/21
17:35
01/21/22
17:35
SBBTF

Schibsted

$37.04 /

+ (+0.00%)

Barclays lowered the…

Barclays lowered the firm's price target on Schibsted to NOK 485 from NOK 565 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
SBBTF Schibsted
$37.04 /

+ (+0.00%)

01/21/22 Nordea
Schibsted upgraded to Strong Buy from Buy at Nordea
01/20/22 JPMorgan
Schibsted price target lowered to NOK 362 from NOK 438 at JPMorgan
12/10/21 Morgan Stanley
Schibsted downgraded to Equal Weight from Overweight at Morgan Stanley
12/09/21 JPMorgan
Schibsted downgraded to Neutral from Overweight at JPMorgan
Recommendations
Sandvik price target raised to SEK 255 from SEK 252 at Barclays » 17:34
01/21/22
01/21
17:34
01/21/22
17:34
SDVKY

Sandvik

$26.41 /

-0.56 (-2.08%)

Barclays analyst Lars…

Barclays analyst Lars Brorson raised the firm's price target on Sandvik to SEK 255 from SEK 252 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
SDVKY Sandvik
$26.41 /

-0.56 (-2.08%)

SDVKY Sandvik
$26.41 /

-0.56 (-2.08%)

01/21/22 Citi
Sandvik price target raised to SEK 319 from SEK 314 at Citi
01/21/22 Morgan Stanley
Sandvik price target raised to SEK 275 from SEK 269 at Morgan Stanley
01/14/22 Barclays
Sandvik price target raised to SEK 252 from SEK 235 at Barclays
01/13/22 Morgan Stanley
Sandvik price target raised to SEK 269 from SEK 265 at Morgan Stanley
Recommendations
Rio Tinto price target lowered to 4,400 GBp from 4,500 GBp at Barclays » 17:34
01/21/22
01/21
17:34
01/21/22
17:34
RIO

Rio Tinto

$74.36 /

-1.795 (-2.36%)

Barclays analyst Amos…

Barclays analyst Amos Fletcher lowered the firm's price target on Rio Tinto to 4,400 GBp from 4,500 GBp and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

01/20/22 Liberum
Rio Tinto downgraded to Sell from Hold at Liberum
01/14/22 Barclays
Rio Tinto price target raised to 4,500 GBp from 4,200 GBp at Barclays
01/13/22 JPMorgan
Rio Tinto price target lowered to 4,840 GBp from 4,900 GBp at JPMorgan
01/07/22 Berenberg
Rio Tinto upgraded to Buy after underperformance at Berenberg
RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

RIO Rio Tinto
$74.36 /

-1.795 (-2.36%)

Recommendations
Rightmove price target raised to 630 GBp from 575 GBp at Barclays » 17:33
01/21/22
01/21
17:33
01/21/22
17:33
RTMVY

Rightmove

$18.01 /

-0.19 (-1.04%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross raised the firm's price target on Rightmove to 630 GBp from 575 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
RTMVY Rightmove
$18.01 /

-0.19 (-1.04%)

01/20/22 Goldman Sachs
Rightmove resumed with a Neutral at Goldman Sachs
10/19/21 JPMorgan
Rightmove price target raised to 753 GBp from 724 GBp at JPMorgan
09/21/21 Citi
Rightmove price target raised to 555 GBp from 450 GBp at Citi
09/15/21 Liberum
Rightmove re-initiated with a Buy at Liberum
Recommendations
Richemont price target raised to CHF 165 from CHF 155 at Barclays » 17:33
01/21/22
01/21
17:33
01/21/22
17:33
CFRUY

Richemont

$14.52 /

-0.64 (-4.22%)

Barclays analyst Carole…

Barclays analyst Carole Madjo raised the firm's price target on Richemont to CHF 165 from CHF 155 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
CFRUY Richemont
$14.52 /

-0.64 (-4.22%)

01/20/22 UBS
Richemont price target raised to CHF 184 from CHF 169 at UBS
01/18/22 Morgan Stanley
Richemont price target raised to CHF 165 from CHF 152 at Morgan Stanley
01/04/22 Barclays
Richemont price target raised to CHF 155 from CHF 150 at Barclays
12/21/21 Bryan Garnier
Richemont upgraded to Buy from Neutral at Bryan Garnier
CFRUY Richemont
$14.52 /

-0.64 (-4.22%)

Recommendations
Prosus price target lowered to EUR 115.90 from EUR 121 at Barclays » 17:32
01/21/22
01/21
17:32
01/21/22
17:32
PROSY

Prosus

$17.32 /

-0.08 (-0.46%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Prosus to EUR 115.90 from EUR 121 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
PROSY Prosus
$17.32 /

-0.08 (-0.46%)

PROSY Prosus
$17.32 /

-0.08 (-0.46%)

01/20/22 Goldman Sachs
Prosus resumed with a Buy at Goldman Sachs
01/10/22 Credit Suisse
Prosus price target lowered to EUR 137 from EUR 140 at Credit Suisse
11/26/21 UBS
Prosus price target raised to EUR 97 from EUR 89 at UBS
11/23/21 JPMorgan
Prosus price target lowered to EUR 114 from EUR 135.90 at JPMorgan
Recommendations
Petra Diamonds price target lowered to 65 GBp from 70 GBp at Barclays » 17:31
01/21/22
01/21
17:31
01/21/22
17:31
PDLMF

Petra Diamonds

$1.10 /

-0.14 (-11.29%)

Barclays analyst Ian…

Barclays analyst Ian Rossouw lowered the firm's price target on Petra Diamonds to 65 GBp from 70 GBp and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
PDLMF Petra Diamonds
$1.10 /

-0.14 (-11.29%)

01/14/22 Barclays
Petra Diamonds price target raised to 70 GBp from 1 GBp at Barclays
10/27/21 Panmure Gordon
Petra Diamonds downgraded to Hold from Buy at Panmure Gordon
Recommendations
Persimmon price target lowered to 2,250 GBp from 2,500 GBp at Barclays » 17:31
01/21/22
01/21
17:31
01/21/22
17:31
PSMMY

Persimmon

$69.72 /

-0.22 (-0.31%)

Barclays analyst Gavin…

Barclays analyst Gavin Jago lowered the firm's price target on Persimmon to 2,250 GBp from 2,500 GBp and keeps an Underweight rating on the shares.

ShowHide Related Items >><<
PSMMY Persimmon
$69.72 /

-0.22 (-0.31%)

01/21/22 UBS
Persimmon price target lowered to 2,650 GBp from 3,015 GBp at UBS
01/20/22 Morgan Stanley
Persimmon price target lowered to 2,900 GBp from 3,250 GBp at Morgan Stanley
01/14/22 JPMorgan
Persimmon price target raised to 3,580 GBp from 3,530 GBp at JPMorgan
01/14/22 Deutsche Bank
Persimmon downgraded to Hold from Buy at Deutsche Bank
Recommendations
Naspers price target lowered to ZAR 4,050 from ZAR 4,365 at Barclays » 17:30
01/21/22
01/21
17:30
01/21/22
17:30
NPSNY

Naspers

$33.65 /

-0.67 (-1.95%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Naspers to ZAR 4,050 from ZAR 4,365 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
NPSNY Naspers
$33.65 /

-0.67 (-1.95%)

01/20/22 Goldman Sachs
Naspers resumed with a Buy at Goldman Sachs
11/03/21 Barclays
Naspers price target raised to ZAR 4,370 from ZAR 3,300 at Barclays
10/08/21 Barclays
Naspers price target lowered to ZAR 3,300 from ZAR 3,945 at Barclays
10/04/21 Morgan Stanley
Naspers resumed with an Overweight at Morgan Stanley
Recommendations
Moneysupermarket.com price target lowered to 260 GBp from 275 GBp at Barclays » 17:29
01/21/22
01/21
17:29
01/21/22
17:29
MYSRF

Moneysupermarket.com

$2.57 /

+ (+0.00%)

Barclays analyst Andrew…

Barclays analyst Andrew Ross lowered the firm's price target on Moneysupermarket.com to 260 GBp from 275 GBp and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
MYSRF Moneysupermarket.com
$2.57 /

+ (+0.00%)

12/21/21 Citi
Moneysupermarket.com upgraded to Buy from Neutral at Citi
11/01/21 Credit Suisse
Moneysupermarket.com price target raised to 265 GBp at Credit Suisse
10/20/21 UBS
Moneysupermarket.com price target lowered to 320 GBp from 345 GBp at UBS
10/20/21 Berenberg
Moneysupermarket.com upgraded to Buy from Hold at Berenberg

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.